In This Section      
 

Search Results

Title:
9875 Phase 2 Study of AT13387 (onalespib) in ALK+ ALCL, MCL, and BCL-6+ DLBCL
Protocol Number:
J1690
Phase:
Phase II
Physician:
Nina Wagner-Johnston
Sites:
Johns Hopkins Kimmel Cancer Center in Baltimore
Purpose:
To view overall response rate to single agent AT13387 (onalespib) as measured by the proportion of partial and complete responses in patients with ALK+ ALCL, MCL, and BCL6+ DLBCL. To view progression free survival and overall survival, as well as duration of response of single agent AT13387 (onalespib). To explore safety and tolerability of single agent AT13387 (onalespib) in patients with ALK+ ALCL, MCL, and BCL6+ DLBCL.
Eligibility:
ALK+ ALCL or MCL or BCL6+ DLBCLALK+ALCL must be relapsed and or refractory to prior therapy which must include an anthracycline and brentuximabMCL must be relapsed and or refractory to prior therapy which must have included ibrutinibBCL6+ DLBCL must be relapsed and or refractory to prior therapy which must have included an anthracyclineMeasurable disease not previously irradiated, defined as at least one lesion that can be measured in at least one dimension as greater than / equal to 20mm ( greater than / equal to 2cm) with conventional imaging or greater than / equal to 10mm with spiral CT scanAge greater than / equal to 18 yearsLife expectancy greater than 3 monthsnormal organ and bone marrow functionNo leptomeningeal or brain metastasesNo uncontrolled intercurrent illness
Treatment:
AT13387 (onalespib) is administered on an outpatient basis as an IV infusion over 60 minutes. Infusion occurs on days 1,2,8,9,15 and 16 every 28 days.
Population:
Adult
Last Update
03/05/2019 05:03 AM